

# 

Significant progress has been made in the treatment of advanced BRAFV600-mutant melanoma.

Encorafenib in combination with binimetinib is a well-tolerated and effective treatment option, providing sustained progression-free and overall survival benefit in unresectable or metastatic setting.

The focus has shifted to early-stage disease in order to prevent recurrence, it has been estimated that 18% of stage IIB and 25% stage IIC patients die due to melanoma within 10 years from the diagnosis [Gershenwald et al 2017], indicating an unmet medical need.

# - STUDY DESIGN


COLUMBUS-AD study is an international randomized, placebo-controlled, triple-blind, multicenter Phase III trial evaluating adjuvant encorafenib + binimetinib against placebo in patients with fully resected stage IIB/C BRAFV600-mutant melanoma.

Participants with fully resected cutaneous melanoma and documented BRAFV600E/K status by central assay will be randomized 1 to 1 to receive either treatment with encorafenib and binimetinib or their two placebos for 12 months. The randomization will be stratified according to the stage of the disease according to AJCC version 8 between:

(stage IIB (i.e., pT3b or pT4a))

stage IIC (i.e., pT4b)

The main analysis of RFS will be conducted after approximately 166 RFS events have been observed, which is predicted to occur 4.4 years from the accrual of the first participant. In total, patients will be followed-up for 10 years from randomization. (Figure 1)



# Phase III Study of Adjuvant Encorafenib Plus Binimetinib Versus Placebo In Fully Resected Stage IIB/C **BRAFV600-Mutated Melanoma : COLUMBUS-AD Study Design**

Alexander C. J. van Akkooi<sup>1</sup>, Axel Hauschild<sup>2</sup>, Georgina V. Long<sup>3</sup>, Mario Mandala<sup>4</sup> Michal Kicinski<sup>5</sup>, Isabelle Klauck<sup>6</sup>, Monia Ouali<sup>6</sup>, Paul C. Lorigan<sup>7</sup>, Alexander M. M. Eggermont<sup>8</sup> <sup>1</sup>Melanoma Institute Australia, the University of Sydney, and Mater and Royal Hospitals, Sydney, and Mater and Royal North Shore Hospitals, Sydney, and NSW, Australia; <sup>4</sup>University of Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy; <sup>5</sup>EORTC Headquarters, Brussels, Belgium; <sup>6</sup>Pierre Fabre, France; <sup>7</sup>Christie NHS Foundation Trust, Manchester, United Kingdom; <sup>8</sup>University Medical Center Utrecht, Utrecht, the Netherlands.

Long-term Follow-up: 10 years from randomization

Primary endpoint: RFS

**Secondary endpoints:** DMFS, OS, QoL, AEs, PK

**Exploratory endpoint:** Role of ctDNA

The purpose of the Columbus-AD (NCT05270044) study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAFV600E/K-mutant stage IIB/C melanoma versus Placebo.

# Conclusion

COLUMBUS-AD is the first study to evaluate a combination of **BRAFi/MEKi in high-risk stage II** adjuvant melanoma.

This study will evaluate whether the combination of encorafenib and binimetinib can decrease the risk for recurrence and improve distant metastasis-free survival and overall survival versus placebo in fully resected IIB/C **BRAFV600E/K-mutant melanoma.** 

# **Pre-Screening**

Male or female  $\geq$  18 years of age

Fully resected, with tumour free margins, and histologically/pathologically confirmednewdiagnosisofstageIIB-IIC(pT3b-pT4bN0)cutaneousmelanoma

Sentinel node biopsy within 14 weeks from initial diagnosis of melanoma

Sentinel node staged node negative (pN0)

mutation

## Screening

Melanoma confirmed centrally to be BRAFV600E/K mutation-positive

Participant still free of disease as evidenced by the required baseline imaging and physical/dermatological assessments performed respectively within 6 weeks and 2 weeks before randomization

No more than 12 weeks elapsed between full surgical resection (including Sentinel Lymph Node Biopsy) and randomization

Recovered from definitive surgery (e.g., complete wound healing, no uncontrolled wound infections or indwelling)

ECOG performance status of 0 or 1

Adequate hematological, renal, hepatic, cardiac and coagulation functions

Negative serum beta-HCG test

Female patients of childbearing potential and male patients must agree to follow effective contraception method

## Primary endpoint

**Recurrence-free survival** (RFS)

Study NCT number 05270044 at clinicaltrial.gov

# **Inclusion criteria**

Available tumour sample for central determination of the BRAFV600E/K

### Secondary endpoints

Distant metastasis-free survival (DMFS) **Overall survival (OS)** Safety & tolerability (AEs) Patient-reported health-related Quality of Life (HRQoL) Pharmacokinetic data (PK)

**Exploratory endpoints** 

**Role of circulating** tumor DNA (ctDNA)